Sermorelin for Age-Related GH Decline

Candidate profile

Adults aged 40 and older with clinical signs consistent with age-related growth hormone decline — reduced lean muscle mass, increased adiposity (particularly truncal), diminished recovery from exercise, thinning skin, disrupted sleep architecture, and subjective loss of vitality. Ideally confirmed by laboratory findings: IGF-1 in the lower quartile of the age-adjusted reference range, or documented decline from previous baselines.

Sermorelin is not appropriate for adults with normal-range IGF-1 levels seeking supraphysiologic enhancement. It is a replacement-oriented strategy — restoring GH pulsatility to a more youthful pattern, not amplifying it beyond physiological norms.

Approach

Subcutaneous sermorelin administration before sleep, timed to coincide with the natural nocturnal GH secretion window. Sermorelin is a GHRH analog (amino acids 1-29) that stimulates the pituitary through the body's own regulatory axis — preserving negative feedback and pulsatile secretion rather than creating flat, supraphysiologic GH levels like exogenous GH.

Protocol design

Primary peptide: Sermorelin, 200–300 mcg per dose

Route: Subcutaneous injection (abdomen or deltoid)

Timing: 30–60 minutes before sleep, on an empty stomach. Eating close to injection blunts GH release due to insulin-mediated suppression.

Schedule: 5 days on, 2 days off (weekdays on, weekends off is a common framework). The off days help prevent pituitary desensitization to GHRH stimulation.

Duration: 3–6 months minimum. GH-mediated tissue remodeling — collagen synthesis, body composition shifts, bone density improvements — operates on a slow timeline. Expecting meaningful anti-aging results before 3 months is unrealistic.

Optional combination:

• Ipamorelin, 100–200 mcg co-administered at bedtime. The GHRH + GHRP pairing produces synergistic GH release substantially greater than either peptide alone.
• CJC-1295/Ipamorelin as an alternative — longer-acting GHRH stimulation, reduced injection frequency, but less pulsatile release profile.

Timeline & milestones

Weeks 1–2: Improved sleep quality is typically the earliest signal. Deeper, more restorative sleep with more vivid dreams — consistent with enhanced slow-wave sleep driven by increased nocturnal GH pulsatility.

Weeks 3–6: Subjective improvements in recovery from exercise, morning energy, and skin hydration. These are early functional signals, not yet reflecting structural tissue remodeling.

Months 2–3: Body composition begins shifting — modest reduction in truncal adiposity, improved muscle tone with consistent resistance training. Skin thickness and texture may improve as collagen synthesis increases.

Months 4–6: Full anti-aging benefit window. Laboratory confirmation: repeat IGF-1 should show meaningful increase from baseline. Functional markers — exercise recovery, body composition, skin quality, cognitive sharpness — should demonstrate cumulative improvement.

Monitoring

• IGF-1 levels: Baseline, 8-week, and 6-month measurements. Target is mid-range for a 30–40-year-old reference, not the upper extreme
• Fasting glucose and HbA1c: GH antagonizes insulin — monitor for glucose elevation, especially in individuals with pre-existing insulin resistance
• Body composition: DEXA scan at baseline and 6 months for objective lean mass and fat mass tracking
• Sleep quality: Subjective tracking and wearable data — improved deep sleep percentage is an early biomarker of response
• Joint symptoms: Mild fluid retention or carpal tunnel-like tingling can occur if GH elevation overshoots; these are dose-reduction signals

When to adjust

• No improvement in sleep quality by week 3: Confirm injection timing and fasting compliance. If adherence is confirmed, increase to 300 mcg or add ipamorelin.
• Carpal tunnel symptoms or joint swelling: Reduce dose by 50 mcg — GH/IGF-1 elevation above the comfortable range. Dose-dependent and reversible.
• Fasting glucose increase >10 mg/dL: Reassess risk-benefit. In insulin-resistant individuals, consider lower doses or discontinuation.
• IGF-1 not increasing after 3 months: Consider pituitary reserve testing. Some individuals with advanced somatopause lack sufficient pituitary capacity for GHRH stimulation and may require exogenous GH.